|
시장보고서
상품코드
2032334
항체약물접합체(ADC) 시장 보고서 : 구성 요소, 표적, 용도, 최종 사용자, 지역별(2026-2034년)Antibody Drug Conjugates Market Report by Component, Target, Application, End User, and Region 2026-2034 |
||||||
세계의 항체약물접합체(ADC) 시장 규모는 2025년에 112억 달러에 이르렀습니다. 향후 IMARC Group은 2026-2034년에 걸쳐 CAGR 18.68%를 나타내 2034년까지 시장 규모가 548억 달러에 이를 것으로 예측했습니다.
항체약물접합체는 종양을 표적으로 하는 항체에 세포독성 이펙터 분자가 화학적으로 결합된 매우 강력한 생물학적 제제입니다. 생분해성 링커를 통해 단일클론항체(mAb)에 결합시켜 건강한 조직과 병변 조직을 섬세하게 구분하고, 환부 세포에 세포독성 항암제를 전달합니다. ADC는 표준 화학요법용 생물학적 활성 화합물에 비해 mAb의 세포 사멸 능력을 높이고, 약물의 내약성을 개선하며, 전신 노출을 제한하는 데 도움이 됩니다. 현재 ADC는 위산과 단백질 분해 효소에 의해 mAb가 분해되는 것을 방지하기 위해 정맥으로 투여하여 혈류로 보내집니다.
항체약물접합체(ADC) 시장 동향
앉아서 생활하는 습관과 흡연과 음주를 습관적으로 하는 사람들이 증가하면서 전 세계적으로 암 유병률이 증가하고 있습니다. 이와 더불어, 비용 효율적이고 효과적인 암 치료법에 대한 수요 증가는 시장 성장을 가속하는 주요 요인 중 하나입니다. 이와는 별도로 기존 링커는 종종 표적에 도달하지 않고 약물을 방출하여 오프 타겟 독성을 유발하여 ADC 개발에 심각한 영향을 미치고 있습니다. 그 결과, 주요 기업들은 기존 화학적 트리거를 최적화하고 고선택성 링커를 생성하기 위한 새로운 화학적 트리거를 개발하기 위해 연구 개발(R&D) 프로젝트에 지속적으로 투자하고 있습니다. 또한, 안정적이고 균일한 ADC를 제조하기 위한 새로운 링커-항체 결합 방식과 페이로드 확장을 위한 추가적인 링커-페이로드 결합 방식도 고안하고 있습니다. 또한, 흡수, 분포, 대사, 배설(ADME)의 개선에 초점을 맞추고 있으며, 이는 시장 전망을 긍정적으로 만들고 있습니다. 기타 의료 인프라의 대폭적인 개선, 암 치료에 사용할 수 있는 치료법에 대한 인식 증가, 절단 가능한 링커 기술의 도입 등 주요 요인들이 시장 성장을 가속할 것으로 예측됩니다.
본 보고서에서 답변을 얻을 수 있는 주요 질문
- 지금까지의 세계의 항체약물접합체(ADC) 시장 동향은 어떠했으며, 향후 몇 년 동안 어떻게 변화할 것인가?
- 코로나19는 세계의 항체약물접합체(ADC) 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은?
- 구성 요소별 시장 분석은 어떻게 이루어지고 있는가?
- 대상별 시장 분석은?
- 용도에 따른 시장 내역은?
- 최종 사용자에 따른 시장 분석은 어떻게 이루어지고 있는가?
- 이 산업의 가치사슬의 각 단계는?
- 이 산업의 주요 촉진요인과 과제는?
- 세계 항체약물접합체(ADC) 시장의 구조는 어떻게 되어 있으며, 주요 진출 업체는 누구인가?
- 산업 내 경쟁의 강도는 어느 정도입니까?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 항체약물접합체(ADC) 시장
제6장 시장 분석 : 구성 요소별
제7장 시장 분석 : 대상별
제8장 시장 분석 : 용도별
제9장 시장 분석 : 최종 사용자별
제10장 시장 분석 : 지역별
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
KTH 26.05.15The global antibody drug conjugates market size reached USD 11.2 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 54.8 Billion by 2034, exhibiting a growth rate (CAGR) of 18.68 % during 2026-2034.
Antibody drug conjugates (ADCs) are highly potent biological drugs comprising tumor-targeting antibodies, which are chemically attached to a cytotoxic effector molecule. They deliver cytotoxic anticancer agents to affected cells by connecting them to monoclonal antibodies (mAb) through biodegradable linkers and allowing sensitive bifurcation between healthy and diseased tissues. They assist in increasing the cell-killing potential of mAb, enhancing drug tolerability, and limiting systematic exposure compared to standard chemotherapy bioactive compounds. At present, they are administered intravenously into the bloodstream to avoid gastric acid and proteolytic enzyme degradation of the mAb.
ANTIBODY DRUG CONJUGATES MARKET TRENDS:
Due to sedentary lifestyles and the rising number of individuals who smoke and drink regularly, there is an increase in the prevalence of cancer around the world. This, in confluence with the escalating demand for cost-effective and successful cancer treatments, represents one of the key factors bolstering the growth of the market. Apart from this, the existing linkers often release payloads nonspecifically and lead to off-target toxicity, which severely affects the development of ADCs. As a result, leading players are continuously funding their research and development (R&D) projects to optimize the existing chemical triggers and develop novel chemical triggers to generate highly selective linkers. They are also coming up with novel linker-antibody attachments to produce stable and homogenous ADCs and additional linker-payload attachments to allow the expansion of payloads. Moreover, they are focusing on improving the absorption, distribution, metabolism, and excretion, which is creating a favorable market outlook. Other major factors, including considerably improving healthcare infrastructure, increasing awareness about therapies available for cancer treatments, and the introduction of cleavable linker technology, are anticipated to propel the market growth.
KEY MARKET SEGMENTATION:
Breakup by Component:
- Monoclonal Antibodies
- Linker
- Cytotoxic Agent
- Others
Breakup by Target:
- Antibody-Protein Toxin Conjugates
- Antibody-Chelated Radionuclide Conjugates
- Antibody-Small-Molecule Drug Conjugates
- Antibody-Enzyme Conjugates
Breakup by Application:
- Lymphoma
- Ovarian Cancer
- Lung Cancer
- Breast Cancer
- Brain Tumor
- Others
Breakup by End User:
- Hospitals
- Specialized Cancer Centers
- Academic Research Institutes
- Biotechnology Companies
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca plc, Celldex Therapeutics Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline Plc, ImmunoGen Inc, Pfizer Inc., Sanofi S.A., Seagen Inc., Sorrento Therapeutics Inc. and Takeda Pharmaceutical Company Ltd.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the global antibody drug conjugates market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global antibody drug conjugates market?
- What are the key regional markets?
- What is the breakup of the market based on the component?
- What is the breakup of the market based on the target?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global antibody drug conjugates market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Antibody Drug Conjugates Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Component
- 6.1 Monoclonal Antibodies
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Linker
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Cytotoxic Agent
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Target
- 7.1 Antibody-Protein Toxin Conjugates
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Antibody-Chelated Radionuclide Conjugates
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Antibody-Small-Molecule Drug Conjugates
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Antibody-Enzyme Conjugates
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Application
- 8.1 Lymphoma
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Ovarian Cancer
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Lung Cancer
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Breast Cancer
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Brain Tumor
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
- 8.6 Others
- 8.6.1 Market Trends
- 8.6.2 Market Forecast
9 Market Breakup by End User
- 9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Specialized Cancer Centers
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Academic Research Institutes
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Biotechnology Companies
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
- 9.5 Others
- 9.5.1 Market Trends
- 9.5.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 ADC Therapeutics SA
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.2 Astellas Pharma Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 AstraZeneca plc
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Celldex Therapeutics Inc.
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 F. Hoffmann-La Roche AG
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.6 Gilead Sciences Inc.
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 GlaxoSmithKline Plc
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 ImmunoGen Inc
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 Pfizer Inc.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Sanofi S.A.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Seagen Inc.
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
- 15.3.12 Sorrento Therapeutics Inc.
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 Financials
- 15.3.13 Takeda Pharmaceutical Company Ltd.
- 15.3.13.1 Company Overview
- 15.3.13.2 Product Portfolio
- 15.3.13.3 Financials
- 15.3.13.4 SWOT Analysis
- 15.3.1 ADC Therapeutics SA
